ApoE Mimetics Enhance Drug Delivery Across Blood-Brain Barrier for Neurodegenerative and Cardiovascular Diseases

Effective drug delivery to the brain remains a formidable challenge in treating neurodegenerative diseases due to the highly restrictive Blood-Brain Barrier (BBB). Conventional therapies often fail to achieve therapeutic concentrations in the central nervous system (CNS), limiting their efficacy. Apolipoprotein E (ApoE) mimetic peptides, synthetic analogues of natural ApoE's lipid-binding domains, have emerged as a promising strategy to overcome this barrier. These mimetics leverage the natural transport mechanisms of ApoE, which interacts with low-density lipoprotein receptors (LDLR) family members, to facilitate drug entry into the brain and targeted cells.

This comprehensive review synthesizes advances in apolipoprotein E (ApoE) mimetic peptide design and their application within nanocarrier systems for targeted drug delivery. It evaluates various nanocarrier designs, including reconstituted low-high density lipoproteins, polymeric nanoparticles, and liposomal systems, focusing on their ability to improve drug delivery to the central nervous system and cardiovascular system. The review also emphasizes new multifunctional systems where ApoE mimetics are conjugated with therapeutic or diagnostic molecules, enabling targeted imaging, disease-site delivery, and disease-specific activity. The authors discuss the mechanisms by which ApoE mimetics enhance drug delivery and analyze strategies for managing current limitations.

The review highlights that ApoE-functionalized nanoparticles and multifunctional liposomes demonstrate significantly improved BBB translocation and cellular internalization compared to conventional delivery vehicles. These advanced systems also exhibit enhanced Amyloid-beta (Aβ) affinity, a critical factor for Alzheimer's disease therapies. The integration of ApoE mimetics into nanocarriers facilitates targeted delivery of therapeutic drugs, enabling imaging of specific disease areas and localized therapeutic action. This approach holds substantial promise for delivering compounds that require effective intracranial delivery, such as antisense oligonucleotides (ASOs), which traditionally struggle with BBB penetration. The review underscores the potential of these systems to overcome limitations of natural compounds like luteolin, which possess potent anti-neuroinflammatory properties but face delivery hurdles. > ApoE mimetics, when incorporated into nanocarriers, consistently improve BBB translocation, cellular internalization, and Aβ affinity, paving the way for more effective CNS drug delivery.